Clinical Trials
2 trialsNCT01290692 2023-07-03
Study To Test the Safety and Efficacy of TVI-Brain-1 As A Treatment for Recurrent Grade IV Glioma
TVAX Biomedical
Phase 2 Completed
NCT02754362 2020-01-13
A Toll-like Receptor Agonist as an Adjuvant to Tumor Associated Antigens (TAA) Mixed With Montanide ISA-51 VG With Bevacizumab for Patients With Recurrent Glioblastoma
NYU Langone Health
Phase 2 Withdrawn